Timing makes a difference in how a given location experiences a biotech boom. Jim Hayward, currently of Applied DNA Sciences, worked in the UK in the 1980s, and found that the differences between the US and the UK meant that it was easier than expected to find funding. Here, he’s talking about his work as a postdoc with biospectroscopist Dennis Chapman: “This was in 1984, ’85. The crest of the biotech revolution in the US had already preceded that in Europe by maybe as much as a decade. When we filed our patents, there really was no biotech presence in Europe. Remarkably, money began to chase us.”